Lunit Oncology

🌲Merry #Christmas and Happy #Holidays from all of us at #Lunit Oncology! We are wishing the happiest and warmest holidays to our partners, healthcare professionals, and the medical community. Your support, engagement and passion drive us to keep pushing boundaries in #AI and #digitalpathology to ultimately help more patients. Here’s to another amazing year in #2025. Stay tuned for more updates, insights and innovations coming your way! 🎆

2024 has been an exciting year for #Lunit! 🚀 🤝The partnership with #AstraZeneca to develop AI-powered #digitalpathology risk assessment tools using #LunitSCOPE genotype predictor was a milestone to helping more patients getting the right treatment. 👥It was amazing to connect with industry professionals and collaborate at conferences including #AACR, #ASCO, #WorldCDx, #PathVisions and #SITC. We look forward to staying in touch and showcasing our latest advancement. Together with our partners, we #Lunitians will continue to push the boundaries of what’s possible in conquering cancer through AI in 2025 🌅

🔬 We’re excited to announce our new publication on #LunitSCOPE uIHC (#universal IHC)! This new study highlights the robust performance of the multi-cohort trained model of #uIHC, which outperformed conventional single-cohort models in analyzing unseen #IHC images across a wide variety of cancer types and biomarker stains. Now developed further, and commercialized as #LunitSCOPE uIHC, the model enables advanced biomarker formation from even singleplex IHC, with subcellular stain localization, continuous intensity scoring, and cell type identification. Click the link below to see the full article: #lunit #uIHC https://lnkd.in/gDmb7Awm

New findings from the Friends of Cancer Research Digital PATH Project were presented at the San Antonio Breast Cancer Symposium #SABCS24 demonstrating the level of agreement of HER2 biomarker assessment across independently developed computational #pathology models. #Lunit is a co-author for this poster. These preliminary findings suggest that the level of agreement of predicted HER2 scores across models is similar to published agreement measures across pathologists.  - View the poster here: https://lnkd.in/dk5QPwqB

Look out for our poster in collaboration with #AstraZeneca at #DP-#AI in London. Independent evaluation of an #AI tool to predict EGFR mutation risk - position #20 In this poster, #Lunit presents the robust performance and generalisability of the Lunit #SCOPE Genotype Predictor which is a rapid and low-cost AI solution that can identify potential #EGFR mutated #NSCLC patients by looking at H&E slides. ✅ You can also contact us at oncology@lunit.io and schedule a meeting with us in London. 📆 December 11-12, 2024 🌐 Hilton London Metropole

#Lunit at #DPAI24!  Are you attending the #DigitalPathology & #AI Congress Europe next week? Meet with our team onsite in London! Our Global VP of Business Development, Michael Hreczuck, along with Siraj A., Global VP of Translational Medicine, and Deboleena Sarkar, Ph.D., Director of Business Development will be attending the congress. Reach out if you would like to schedule a meeting with our team and learn more about how AI can help you make headway in #digitalpathology. ✅ You can also contact us at oncology@lunit.io and schedule a meeting with us in London. 📆 December 11-12, 2024 🌐 Hilton London Metropole

Happy #Thanksgiving from all of us at Lunit Oncology! 🍁 We are deeply thankful for our partners, colleagues, and the healthcare community who inspire us every day. Together, we continue to push the boundaries of AI in healthcare to make a meaningful difference in patients' lives. Wishing you a joyful holiday filled with gratitude, warmth, and good health. 🧡 #ThankYou #Gratitude #AIforHealthcare #Lunit

🎉 We’re excited to announce our collaboration with AstraZeneca to develop AI-powered #digitalpathology risk assessment tools for #NSCLC! 🤝 This #partnership leverages #LunitSCOPE Genotype Predictor to enable rapid and convenient prediction of driver #mutations in non-small cell #lungcancer, including Epidermal Growth Factor Receptor (#EGFR) mutations. Together, #Lunit and #AstraZeneca aim to further develop and validate this innovative screening tool. Following validation, we plan to explore its application in real-world settings to assess the risk of lung driver mutations and guide molecular testing efforts. In addition, our collaboration will investigate predictive models for other #molecularbiomarkers using H&E slide analysis, paving the way for future development and robust validation. 👇Click to read the full announcement! 🔗https://lnkd.in/gKdhT_xv #AI #AIdigitalpathology #GenotypePredictor #AZ #Pharma

🌟 Wrapping up an incredible experience at #SITC and #PathVisions 2024! 🎉 We want to extend a huge thank you to everyone we met onsite at #SITC24 and #PathVisions24! It was amazing to connect with industry professionals, share insights, and showcase the latest advancements from Lunit. 📸 Swipe through to see some highlights from our booth! In case you missed it, you can also watch our oral presentation at #SITC, presented by Dr. Derbala. The session recording can be found in the link below and accessed via your SITC ID. https://lnkd.in/grbJai_b  205b: Rapid Oral – Clinical 2 session. Looking forward to staying in touch with all the new connections we made and exploring the exciting opportunities ahead. Here’s to innovation and collaboration! 🌍✨ #ThankYou #Lunit #AI #Innovation #Networking #Grateful Michael Hreczuck Ben Goodwin Deboleena Sarkar, Ph.D. Siraj A. Sherry Kan Ken Nesmith Su-A Yang ChanMi Kim Kyunghyun Paeng

Tomorrow, our Global VP of Translational Medicine, Siraj A., will participate in a #panel discussion on #precisiononcology #drugdevelopment. The #webinar is hosted by Lumanity. See below for more details and register at: https://lnkd.in/gwhS2nfZ 🗓 November 13, 2024 🕚 11 a.m., Eastern Time “Searching in a More Complete Haystack: Using Real-World Data to Guide Precision Oncology Drug Development” ☑ Strategic challenges in precision oncology ☑ Approaches for navigating these uncertainties ☑ The role of real world data and analytic